Navigation Links
DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
Date:8/29/2014

atient enrollment and expansion of certain cohorts during 2013. Partially offsetting these items were higher costs in the current period for protocol development as DelMar plans for registration-directed clinical trials with VAL-083. Decrease in general and administrative costs during the current period was largely due to a reduction in professional fees related to activities associated with the Company's reverse take-over and public listing that occurred during 2013.

"Non-cash expenses associated with stock options, shares or warrants issued for services or the changes in the derivative liability associated with certain warrants do not affect our working capital and are influenced by changes in the Company's share price," stated Mr. Bacha. "We are highlighting expenses net of such charges because this more accurately reflects the operating cash burn associated with our research, drug development and corporate activities. Full details are presented in our financial statements."

Subsequent to the fiscal year end, DelMar received additional funding through the exercise of warrants for cash. These additional moneys provide working capital sufficient to fund the Company's current operations through at least the end of December 2015.

About DelMar PharmaceuticalsDelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI) and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical an
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... SAN FRANCISCO , June 29, 2015 ... 47.54 billion by 2020, according to a new study by Grand ... II diabetes and the presence of high unmet needs in emerging ... China are expected to be two of the most ... lifestyle induced diseases such as obesity and growing global geriatric population ...
(Date:6/29/2015)... CITY, Mo. , June 29, 2015  Missouri ... the 2015 first quarter data from the state,s real-time, ... (NPLEx). States across the United ... Missouri one of 31 across the country ... attempted pseudoephedrine (PSE) purchases at the point of sale.  ...
(Date:6/29/2015)... KING OF PRUSSIA, Pa. , June 29, 2015 ... Alsharabati, MD, University of Alabama at Birmingham, ... 2015 Interlaken Leadership Award for ... global awards program provides monetary grants and/or product supply ... potential role of immunoglobulin (Ig) therapy in the treatment ...
Breaking Medicine Technology:Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 2Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 3Insulin Market To Reach $47.54 Billion By 2020: Grand View Research, Inc. 4CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 2CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient 3
... 5, 2011 In its April issue, published this ... magazine has announced the winners of the fourteenth annual ... (Logo:  https://photos.prnewswire.com/prnh/20101214/LA16070LOGO) Sponsored by MD+DI ... the premier awards program for the medical technology community. ...
... April 5, 2011 RESMED INC. (NYSE: RMD ... will release its results for the third quarter and nine ... press release with ResMed,s results will be issued after 1:00 ... call and webcast to review its results, market trends, and ...
Cached Medicine Technology:37 Innovative Products Win Medical Design Excellence Awards 237 Innovative Products Win Medical Design Excellence Awards 337 Innovative Products Win Medical Design Excellence Awards 4ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2011 Results 2
(Date:6/29/2015)... , ... June 30, 2015 , ... ... set of revised Guidelines for Neuro Musculoskeletal Thermography and Sympathetic Skin Response Studies.* ... Guidelines that were first published in 2006, are intended to aid physicians and ...
(Date:6/29/2015)... ... June 29, 2015 , ... Healthpointe, one of ... John A. Mitamura, MD., PhD into their world-class multidisciplinary team of physicians and ... Long Beach , Irwindale and La Tijera-Los Angeles. , Orthopedic surgeons of ...
(Date:6/29/2015)... ... , ... Mediaplanet has released the first edition of “Heart ... glossy, full-color special section hit newsstands Friday, June 26th, and was distributed within ... with an estimated readership of 1.3 million. The digital component is being distributed ...
(Date:6/29/2015)... YORK, NEW YORK (PRWEB) , ... June 29, ... ... sleep apnea (OSA) is now being offered at NewYork-Presbyterian/Weill Cornell Medical Center. The ... Drug Administration and is an alternative to continuous positive airway pressure (CPAP), the ...
(Date:6/29/2015)... ... June 29, 2015 , ... National HealthCare Associates ... customer service for the 40-center nursing home group. Sixteen of their centers were ... the United States in one or more customer service areas. Those centers received ...
Breaking Medicine News(10 mins):Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 2Health News:American Academy of Thermology Publishes Revised 2015 Guidelines for Neuro-Musculoskeletal Thermography and Sympathetic Skin Response Studies 3Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 2Health News:Renowned Orthopedic and Spine Surgeon Joins Healthpointe in Long Beach 3Health News:Mediaplanet partners with USA TODAY and Kris Letang to raise awareness about the risk of heart attack and stroke 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 2Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 3Health News:NewYork-Presbyterian/Weill Cornell Medical Center Is First in New York to Offer New Alternative Treatment for Sleep Apnea 4Health News:National HealthCare Centers Receive 'Customer Experience Awards' 2Health News:National HealthCare Centers Receive 'Customer Experience Awards' 3Health News:National HealthCare Centers Receive 'Customer Experience Awards' 4
... Foundation site trends indicating measles risk remains highWASHINGTON, ... states - California, Pennsylvania, Maryland and Iowa - ... children living in the United States as well ... of the disease.(Logo: http://www.newscom.com/cgi-bin/prnh/20090108/RedCrossLOGO ...
... disease, experts say , , FRIDAY, April 17 (HealthDay News) -- ... (PTU) in children has been endorsed by the Endocrine Society. ... 9 New England Journal of Medicine , two experts ... and should no longer be used as a first-line treatment ...
... The following statement may be attributed to Amy ... Research: "We are pleased that the National Institutes of ... of creating federal guidelines to remove restrictions on embryonic ... great promise, today,s draft guidelines that would allow federal ...
... makes prevention more difficult, study finds, , , FRIDAY, April ... commit suicide have been diagnosed with a mental disorder. ... death certificates list mental disorder as a contributing factor, ... it more difficult for health-care policymakers to create prevention ...
... the United States Great Depression of 1929 has the ... and well-being across the parameters of occupational, spiritual, emotional, ... pace, people are at risk for suffering lowered self ... Miami,s St. Thomas University Counseling Programs - ...
... Offers SolutionMURFREESBORO, Tenn., April 17 Medication mistakes at ... to a recent national study, and the need for ... to Shane Reeves, D. Pharm and co-owner of Reeves-Sain.Reeves ... system of bottles to a clearer, more easily managed ...
Cached Medicine News:Health News:U.S. Measles Outbreaks Highlight Global Need 2Health News:Drug May Be Dangerous for Kids With Graves' Disease 2Health News:Death Certificates Incomplete for Suicide Victims 2Health News:Good News for Tough Times: Small, Private University Responds to Today's Economic Challenges 2Health News:Medication Mismanagement Is a Growing Danger 2
Dolwick-Reich Condyle periosteal elevator, 17.5 cm, 7"....
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Obwegeser periosteal elevator, angled, 9 mm, 20 cm, 8"....
... Deformity System unites the clinical experience ... and Isola with revolutionary technology developed ... unsurpassed versatility, simplicity and security. Frontier ... versatility for treating a deformity from ...
Medicine Products: